MariaLJisonMD
Pulmonology • Gaithersburg, MDCritical Care Medicine
Senior Medical Lead/Medical Director, AstraZeneca
Dr. Jison is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 MedImmune Way
Gaithersburg, MD 20878
Summary
- Physician/Entreprenuer, Board certified in pulmonary-critical care medicine, experienced in global late phase (Ph3) clinical development, global clinical trials, protocol development, regulatory interactions, advisory boards, and FDA pre-market medical device review. Small business owner and President of Maximus Medical Billing LLC, a professional, multi-specialty medical billing company providing electronic claims submission for physician practices. Part time practicing Pulmonologist
Education & Training
Johns Hopkins UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2000 - 2002
University of North Carolina HospitalsResidency, Internal Medicine, 1996 - 1999
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1996
Certifications & Licensure
MD State Medical License 1999 - 2026
NC State Medical License 1997 - 2022
VA State Medical License 2005 - 2022
Awards, Honors, & Recognition
- CHEST Foundation Humanitarian Award ACCP, 2006
Publications & Presentations
PubMed
- 139 citationsEfficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial.Claus Bachert, Joseph K. Han, Martin Desrosiers, Philippe Gevaert, Enrico Heffler
The Journal of Allergy and Clinical Immunology. 2021-09-29 - 1 citationsBenralizumab efficacy and safety in severe asthma: A randomized trial in Asia.Kefang Lai, Dejun Sun, Ranran Dai, Ronnie Samoro, Hae-Sim Park
Respiratory Medicine. 2024-04-01 - 83 citationsBenralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.Gary T Ferguson, J. Mark FitzGerald, Eugene R. Bleecker, Michel Laviolette, David I. Bernstein
The Lancet. Respiratory Medicine. 2017-07-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
